Liu Kun, Chen Hong, Wang Yuanyuan, Jiang Liping, Li Yi
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Department of Oncology, 920th Hospital of Joint Logistics Support Force, Teaching Hospital of Kunming Medical University, Kunming, China.
Front Cell Dev Biol. 2022 Apr 21;10:846864. doi: 10.3389/fcell.2022.846864. eCollection 2022.
Glioblastoma (GBM) is one of the most prevalent and aggressive cancers worldwide. The overall survival period of GBM patients is only 15 months even with standard combination therapy. The absence of validated biomarkers for early diagnosis mainly accounts for worse clinical outcomes of GBM patients. Thus, there is an urgent requirement to characterize more biomarkers for the early diagnosis of GBM patients. In addition, the detailed molecular basis during GBM pathogenesis and oncogenesis is not fully understood, highlighting that it is of great significance to elucidate the molecular mechanisms of GBM initiation and development. Recently, accumulated pieces of evidence have revealed the central roles of long noncoding RNAs (lncRNAs) in the tumorigenesis and progression of GBM by binding with DNA, RNA, or protein. Targeting those oncogenic lncRNAs in GBM may be promising to develop more effective therapeutics. Furthermore, a better understanding of the biological function and underlying molecular basis of dysregulated lncRNAs in GBM initiation and development will offer new insights into GBM early diagnosis and develop novel treatments for GBM patients. Herein, this review builds on previous studies to summarize the dysregulated lncRNAs in GBM and their unique biological functions during GBM tumorigenesis and progression. In addition, new insights and challenges of lncRNA-based diagnostic and therapeutic potentials for GBM patients were also introduced.
胶质母细胞瘤（GBM）是全球最常见且侵袭性最强的癌症之一。即便采用标准联合疗法，GBM患者的总生存期也仅为15个月。缺乏经过验证的早期诊断生物标志物是GBM患者临床结局较差的主要原因。因此，迫切需要鉴定更多用于GBM患者早期诊断的生物标志物。此外，GBM发病机制和肿瘤发生过程中的详细分子基础尚未完全明确，这凸显了阐明GBM起始和发展分子机制的重要性。最近，越来越多的证据表明长链非编码RNA（lncRNA）通过与DNA、RNA或蛋白质结合，在GBM的肿瘤发生和进展中发挥核心作用。靶向GBM中的这些致癌lncRNA可能有助于开发更有效的治疗方法。此外，深入了解GBM起始和发展过程中lncRNA失调的生物学功能及其潜在分子基础，将为GBM早期诊断提供新的见解，并为GBM患者开发新的治疗方法。在此，本综述基于以往研究，总结了GBM中失调的lncRNA及其在GBM肿瘤发生和进展过程中的独特生物学功能。此外，还介绍了基于lncRNA的GBM患者诊断和治疗潜力的新见解和挑战。
